Aspira Women's Health Files Q2 10-Q, Details Stock Offerings

TL;DR

Aspira Women's Health 10-Q filed: Q2 financials out, stock deals and warrants detailed. Financing continues.

AI Summary

Aspira Women's Health Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business activities, including details on stock offerings and warrant agreements. Key events mentioned include a Purchase Agreement on January 24, 2024, and a subsequent event related to an At-The-Market Offering Agreement with HC Wainwright & Co. on August 2, 2024.

Why It Matters

This filing provides insight into Aspira Women's Health's financial health and strategic financing activities, which can impact investor confidence and future operational capabilities.

Risk Assessment

Risk Level: medium — The company's financial disclosures and ongoing financing activities suggest potential financial pressures or growth-oriented strategies that carry inherent risks.

Key Numbers

• 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
• 2024-01-24 — Purchase Agreement Date (Marks a significant transaction or agreement date.)
• 2024-08-02 — ATM Offering Agreement Date (Highlights a recent financing or capital-raising event.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of reporting period
• January 24, 2024 (date) — Date of Purchase Agreement
• August 2, 2024 (date) — Date of At-The-Market Offering Agreement
• HC Wainwright & Co. (company) — Underwriter for At-The-Market Offering

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share AWH The Nasdaq Capital Ma

Filing Documents

• awh-20240630.htm (10-Q) — 1730KB
• awh-ex10_3.htm (EX-10.3) — 29KB
• awh-ex10_4.htm (EX-10.4) — 23KB
• awh-ex10_5.htm (EX-10.5) — 126KB
• awh-ex31_1.htm (EX-31.1) — 14KB
• awh-ex31_2.htm (EX-31.2) — 14KB
• awh-ex32_1.htm (EX-32.1) — 10KB
• 0000950170-24-096220.txt ( ) — 7464KB
• awh-20240630.xsd (EX-101.SCH) — 1103KB
• awh-20240630_htm.xml (XML) — 1153KB

Financial Statements (unaudited)

Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2024 and 2023 2 Condensed Consolidated Statements of Changes in Stockholders' (Deficit) Equity for the three and six months ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 5 Notes to Condensed Consolidated Financial Statements 6 Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 30 Item 4

Controls and Procedures

Controls and Procedures 30 PART II Other Information 32 Item 1

Legal Proceedings

Legal Proceedings 32 Item 1A

Risk Factors

Risk Factors 32 Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 33 Item 3 Defaults Upon Senior Securities 33 Item 4 Mine Safety Disclosures 33 Item 5 Other Information 33 Item 6 Exhibits 34

SIGNATURES

SIGNATURES 35 The following are registered and unregistered trademarks and service marks of Aspira Women's Health Inc.: VERMILLION SM , Aspira Women's Health , OVA1 , OVERA , ASPiRA LABS , OvaCalc , OVASUITE SM , ASPiRA GenetiX SM , OVA1PLUS , OVAWATCH , EndoCheck SM , OVAInherit SM , Aspira Synergy , OVA360 SM , ASPIRA IVD SM , and YOUR HEALTH, OUR PASSION .

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS Aspira Women's Health Inc. Condensed Consolidated Balance Sheets (unaudited) (Amounts in Thousands, Except Share and Par Value Amounts) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 962 $ 2,597 Accounts receivable, net of reserves of $ 0 and $ 15 , as of June 30, 2024 and December 31, 2023, respectively 1,445 1,459 Prepaid expenses and other current assets 618 997 Inventories 226 227 Total current assets 3,251 5,280 Property and equipment, net 120 165 Right-of-use assets 559 528 Restricted cash - 258 Other assets 31 31 Total assets $ 3,961 $ 6,262 Liabilities and Stockholders' Deficit Current liabilities: Accounts payable $ 1,943 $ 1,261 Accrued liabilities 2,856 2,863 Current portion of long-term debt 316 166 Short-term debt 166 670 Current maturities of lease liabilities 177 159 Total current liabilities 5,458 5,119 Non-current liabilities: Long-term debt 1,264 1,430 Non-current maturities of lease liabilities 437 427 Warrant liabilities 511 1,651 Total liabilities 7,670 8,627 Commitments and contingencies (Note 4) Stockholders' deficit: Common stock, par value $ 0.001 per share, 200,000,000 and 150,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively; 12,825,090 and 10,645,049 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 13 11 Additional paid-in capital 522,740 515,927 Accumulated deficit ( 526,462 ) ( 518,303 ) Total stockholders' deficit ( 3,709 ) ( 2,365 ) Total liabilities and stockholders' deficit $ 3,961 $ 6,262 See accompanying notes to the unaudited condensed consolidated financial statements. 1 Aspira Women's Health Inc. Condensed Consolidated Statements of Operations (unaudited) (Amounts in Thousands, Except Share and

View Full Filing

View this 10-Q filing on SEC EDGAR